Vancouver's AbCellera more than doubles IPO target size

Vancouver's AbCellera more than doubles IPO target size, headed ...

Vancouver antibody developer AbCellera Biologics Inc. more than doubled the target size of its initial public offering Monday to as much as ...

Vancouver's AbCellera more than doubles IPO target size, headed ...

Vancouver's AbCellera more than doubles IPO target size, headed for biggest debut on record for Canadian biotech ; Source. The Globe and Mail ; Faculty Member.

Adjunct professor Carl Hansen featured in media for successful ...

Media features on this success · Ex-UBC prof Carl Hansen now worth more than $4 billion following spectacular AbCellera Biologics IPO · A Canadian ...

With historic financing, AbCellera becomes champion of Canada's ...

Record-breaking IPO values B.C. company at $5.3-billion as shares are set to start trading Friday.

AbCellera boosts IPO target second time in a week, seeks to raise ...

The Vancouver-based company will offer 24,150,000 common shares and grant its underwriters a 30-day option to purchase 3,622,500 additional ...

AbCellera Biologics's Billionaire Boss Planning Hiring Spree in ...

On Thursday, Dr. Hansen spoke publicly for the first time since the IPO, which more than doubled the previous record for a new issue by a ...

AbCellera Biologics: ABCL IPO, Health Care - Renaissance Capital

IPO: AbCellera Biologics (ABCL) - Provides an AI powered drug discovery platform for antibody therapies.

The top 10 biotech IPOs of 2020

The biggest life sciences IPO of 2020 came from what was a little-known Canadian company, AbCellera Biologics, which has more than two dozen ...

424B4 - SEC.gov

This is the initial public offering of common shares of AbCellera Biologics Inc. We are offering 24,150,000 of our common shares. Prior to this offering, there ...

AbCellera shares soar in record-breaking IPO - The Logic

In early December, it more than doubled its expectations, with a target of US$449.7 million and a maximum share price of US$17. A few days ...

A Canadian biotech giant is born: AbCellera stock triples in ... - Darpa

... more than twice as large as the largest previous Canadian biotech IPO, by Repare. Therapeutics Inc. in June. The offering established AbCellera ...

AbCellera continues antibody scale-up at Vancouver plant

According to the firm, the 380,000 square-foot site will support AbCellera's capabilities to develop antibody-based medicines to the clinic. “We have already ...

abcl-424b3.htm - SEC.gov

In December 2020, we completed AbCellera's IPO on the Nasdaq. The ... more than 130 programs with drug developers of all sizes. 16. In August 2021 ...

AbCellera Biologics Inc.

... targets that may otherwise be intractable. Rather than advancing its own clinical pipeline of drug candidates, the Company forges ...

AbCellera Biologics Inc.

The Company partners with companies of all sizes - from innovative biotechnology companies to leading pharmaceutical companies - propelling ...

Beyond COVID-19: AbCellera Partners with Moderna to Develop ...

On its first day of trading, AbCellera's stock more than tripled its initial public offering (IPO) price of $20 a share to $71.91 later that ...

AbCellera kicks off expansion to build integrated antibody shop

Flush with cash from its $555.5 million IPO at the end of 2020, the Canadian antibody specialist broke ground on the first phase of its global ...

AbCellera Biologics Inc. Form S-1 Filed 2021-06-10

we have issued more than $1.0 billion in nonconvertible debt during ... preferred shares during the closing of our IPO then outstanding ...

AbCellera Reports Q3 2024 Business Results

Liquidity – $670.4 million of total cash, cash equivalents, and marketable securities and with approximately $205 million in available non- ...

News - The Japan Society Canada

Vancouver's AbCellera more than doubles IPO target size, headed for biggest debut on record for Canadian biotech ... com/business/article-vancouvers-abcellera- ...